Why GLP-1 Titration Schedules Work With the Kinetics

GLP-1 medications almost always come with a stepwise dose-escalation schedule: start low, hold for a few weeks, step up, repeat. It is easy to read the four-week holds as bureaucratic caution. They are timed to the drug’s pharmacokinetics. Each hold is roughly long enough for blood levels to plateau at the current dose before the next increase raises the ceiling. Understanding that turns the schedule from an arbitrary rulebook into something you can reason about, and you can see the underlying level-versus-time behavior in the Dose Interval Visualizer.

The kinetic reason the steps are ~4 weeks long

Semaglutide has a half-life of about one week. As covered in Steady State Explained, a compound reaches steady state after roughly four to five half-lives of consistent dosing, so for a weekly drug with a one-week half-life, that is about four to five weeks. Wegovy’s label holds most steps for four weeks. That is not a coincidence: it is close to the time levels need to stabilize at each dose before the drug is asked to climb again.

A titration step is essentially “hold here until the level plateaus, then move the plateau up.” Four weeks per step is what that looks like for a once-weekly, ~1-week-half-life drug.

When you increase a dose before levels have plateaued, two things happen at once: the baseline is still drifting upward from the previous step, and you add a larger dose on top. The gut then has to absorb the combined jump. Wait for the plateau first, and each increase is a clean, single step from a known, stable level, a smaller and more predictable change for your body to adapt to.

What the schedule looks like

Wegovy (semaglutide 2.4 mg) is the clearest worked example. Its label escalates the once-weekly injection in defined four-week steps:

Weeks	Weekly dose
1-4	0.25 mg
5-8	0.5 mg
9-12	1.0 mg
13-16	1.7 mg
17+	2.4 mg (maintenance)

The 0.25 mg starting dose is explicitly not a treatment dose. It exists so the gut can begin adapting while levels reach their first plateau, a tolerability step, not a weight-loss step. Each subsequent four-week hold repeats the same logic one rung higher. Tirzepatide follows the same pattern with different numbers; both are laid out in Semaglutide and Tirzepatide Titration Schedules, and the broader “why slow wins” case is made in GLP-1 Dosing and Titration.

Why plateauing first improves tolerability

GLP-1 side effects (nausea, reduced appetite, sometimes vomiting or constipation) are mostly dose-related and tend to be worst right when the dose changes. Two features of the kinetics interact here:

• Accumulation is modest at weekly dosing. With an interval near one half-life, semaglutide’s accumulation ratio is around 2, so levels ride relatively smoothly rather than spiking and crashing each week. That smoothness is part of what makes weekly dosing tolerable at all.
• Adaptation needs a stable target. The gut adapts to a given level over time. If the level is still climbing, adaptation is chasing a moving target. Letting each step plateau gives the body a fixed level to acclimate to before the next challenge.

Step up too early and you compound the two hardest moments (a rising baseline and a dose increase) into one, which is when nausea peaks. The four-week hold spaces those events out.

The schedule is a template, not a countdown

Because the holds are keyed to kinetics, they are also flexible in a principled way. The Wegovy label itself says that if a patient does not tolerate a dose during escalation, the clinician should consider delaying the next increase by four weeks. In kinetic terms: give the level more time at the current plateau, and let adaptation catch up, before moving the ceiling. Staying on a step longer (or stepping back down temporarily) is a normal adjustment, not a failure. If a dose increase feels rough, see GLP-1 Dose Increase Side Effects and talk to your prescriber rather than pushing ahead.

The same reasoning explains a common question about restarting: after a break, levels have washed out over several half-lives, so protocols often re-titrate rather than resuming at the old dose: the plateau has to be rebuilt from a lower baseline. That is covered in Restarting a GLP-1 After a Break.

The takeaway

GLP-1 titration schedules are engineered around the drug’s half-life. Roughly four-week holds give a once-weekly, one-week-half-life drug time to plateau at each dose before the next step raises the ceiling, which keeps each increase a single, clean, well-tolerated jump instead of stacking a rising baseline onto a dose hike. The starting dose is a tolerability step, not a treatment dose, and pausing when side effects are rough is built into the logic, not a deviation from it. Read the schedule as “let it plateau, then step up,” and it stops looking like red tape.

See how levels climb to each plateau in the Dose Interval Visualizer, and use the Peptide Half-Life Visualizer to see the weekly decay behind a semaglutide dose.

This article is educational and not medical advice. GLP-1 dosing and titration should be managed with a prescribing clinician.

Sources

• Wegovy (semaglutide) Dosing and Administration — NovoMedLink (Novo Nordisk)
• Steady State Concentration — StatPearls (NCBI Bookshelf)
• What is Steady-State Concentration in Pharmacokinetics — Allucent